Congress Readies Proposal To Cap NIH Grantees' Salaries

WASHINGTON—Congress wants to cap the salaries that biomedical scientists receive for their work on federal research grants. Although the proposed limit .may not actually shrink the paychecks of individual scientists and will save the National Institutes of Health only about $10 million annually, it represents the latest move in a campaign to force universities to pick up a greater share of the cost of their research faculty. Asking universities to take on that burden, according to feder

Written byJeffrey Mervis
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

WASHINGTON—Congress wants to cap the salaries that biomedical scientists receive for their work on federal research grants. Although the proposed limit .may not actually shrink the paychecks of individual scientists and will save the National Institutes of Health only about $10 million annually, it represents the latest move in a campaign to force universities to pick up a greater share of the cost of their research faculty. Asking universities to take on that burden, according to federal officials, is one way to stretch research dollars during a time of tightening budgets.

The salary cap, part of legislation that sets the budget for the govemment’s education and health agencies, would prevent NIH from paying an investigator more than $120,000 annually in a grant or contract. However, because most scientists allocate only a portion of their time to a particular grant, that limit would be applied as a prorated share of their ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
Image of a man in a laboratory looking frustrated with his failed experiment.
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies